We represent a Southeastern health system in connection with an FDA investigation arising from allegations of potential controlled substances diversion at a hospital facility. We have assisted the client with its internal investigation, responses to agency inquiries, and production of records to the FDA. We continue to advise the health system on controlled substances compliance measures, diversion prevention efforts, staff education, and policy enhancements.